-
Valganciclovir for the Prevention of CMV After Treatment of Rejection with Anti-Lymphocyte Depleting Antibodies in Kidney Transplant Recipients
-
Validation of a Hypertension Risk Calculator for Living Kidney Donors
-
Validation of a Prediction System for Risk of Allograft Loss (iBOX) in Pediatric Kidney Transplant Recipients
-
Validation of Donor Specific Antibody Characteristics Associated with Deleterious Outcomes: A Single Center Study of 940 Kidney Allograft Recipients
-
Validation of Shared T Cell Epitope Analysis as a Tool to Detect Preformed Donor-Reactive CD4+ Memory T-helper Cells
-
Validation of the iBox Surrogate End Point in CNI Free, Belatacept Treated Patients (BENEFIT & BENEFIT-EXT)
-
Validation of the PROMIS® Medication Adherence Scale Among Kidney Transplant Recipients on Tacrolimus
-
Validation of Trugraf Gene Expression Profile in a Multicenter Cohort (TOGETHER Study)
-
Variability In Plasma Donor-derived Cell-free DNA Levels With CLAD More Than 5-years After Lung Transplantation: Pilot Data
-
Variability of Serum Klotho and FGF-23 Levels During the First Two Years After Kidney Transplantation
2022 American Transplant Congress
June 4-8, 2022 in Boston, MA
The ATC program is built in the Eastern Time Zone.